Clinical Trials Logo

Carcinoma, Hepatocellular clinical trials

View clinical trials related to Carcinoma, Hepatocellular.

Filter by:

NCT ID: NCT04111029 Recruiting - Clinical trials for Hepatic Carcinoma Malignant Primary Non-Resectable

Liquid Biopsy in Hepatocellular Carcinoma

HCCGenePanel
Start date: January 16, 2020
Phase:
Study type: Observational

Circulating tumor DNA (ctDNA) carrying tumor-specific sequence alterations has been found in the cell-free fraction of blood. Hepatocellular carcinoma (HCC) specimens are difficult to obtain, and noninvasive methods are required to assess cancer progression and characterize underlying genomic features. Use of 'liquid biopsy' by assessing circulating cell free DNA enables the clinician to offer targeted immunotherapy or signaling pathway inhibitors. It also offers a model to prove response to locoregional or immunotherapy therapy and predict tumor recurrence non-invasively.

NCT ID: NCT04104074 Recruiting - Clinical trials for Hepatocellular Carcinoma

Safety and Efficacy of Radiotherapy Plus Sintilimab for HCC With Portal Vein Tumor Thrombosis

Start date: November 25, 2019
Phase: Phase 1
Study type: Interventional

The proposed study is an open-label, single-center, single arm phase 1b study to evaluate the safety and efficacy of radiotherapy plus sintilimab for HCC with PVTT.

NCT ID: NCT04080154 Recruiting - Clinical trials for Hepatocellular Carcinoma

Study of Anlotinib After Lenvatinib in Patients With Hepatocellular Carcinoma

ALTER-H-002
Start date: September 24, 2019
Phase: Phase 2
Study type: Interventional

This clinical study evaluates the efficacy and safety of anlotinib in patients with hepatocellular carcinoma who have progressed on lenvatinib treatment. It is a single arm, open-label clinical trial conducted in China, and plan to recruit 28 patients. Primary endpoint of the study is Progress Free Survival.

NCT ID: NCT04076631 Recruiting - Clinical trials for Hepatocellular Carcinoma

Surgical Stages of Liver Cirrhosis In Patients With Hepatocellular Carcinoma

Start date: August 1, 2019
Phase:
Study type: Observational

The investigators intend to perform a prospective, multicenter study to establish a set of clinical criteria for surgical stages of liver cirrhosis, which can be implemented to guide the surgical treatment of hepatocellular carcinoma (HCC).

NCT ID: NCT04066543 Recruiting - Clinical trials for Carcinoma, Hepatocellular

TACE Combined With Anlotinib Treatment of Middle-advanced Hepatocellular Carcinoma (HCC) Patients

Start date: August 30, 2019
Phase: Phase 2
Study type: Interventional

This study was designed to evaluate the effectiveness of Anlotinib in middle-advanced Hepatocellular Carcinoma (HCC) Patients.

NCT ID: NCT04053985 Recruiting - Clinical trials for Hepatocellular Carcinoma

The Efficacy of Transarterial Chemoinfusion (TAI) Combine Lenvatinib in Advanced Hepatocellular Carcinoma (HCC)

Start date: January 1, 2018
Phase: Phase 3
Study type: Interventional

evaluation of the efficacy of transarterial chemoinfusion (TAI) combine lenvatinib in advanced hepatocelllar carcinoma

NCT ID: NCT04053972 Recruiting - Clinical trials for Hepatocellular Carcinoma

The Impact on Recurrence Risk of Adjuvant Lenvatinib for Patients With Hepatocellular Carcinoma And Microvascular Invasion (MVI) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial.

Start date: January 31, 2018
Phase: Phase 3
Study type: Interventional

To compare The Impact on Recurrence Risk of Adjuvant Lenvatinib for Patients With Hepatocellular Carcinoma And Microvascular Invasion (MVI) After Hepatectomy.

NCT ID: NCT04052152 Recruiting - Clinical trials for Advanced Hepatocellular Carcinoma

Anlotinib Hydrochloride Combined With Sintilimab Injection in the Treatment of Advanced Hepatocellular Carcinoma (HCC)

Start date: June 10, 2019
Phase: Phase 2
Study type: Interventional

This is a single-arm, open-label and exploratory clinical study of Anlotinib Hydrochloride Capsules combined with Sintilimab injection in the treatment of advanced Hepatocellular Carcinoma (HCC). In oder to observe and evaluate the efficacy and safety of Anlotinib Hydrochloride Capsules combined with Sintilimab injection. Subjects with pathological confirmed Hepatocellular Carcinoma will be enrolled. 21 days as a treatment cycle, Anlotinib 12mg/day(D1-D14 ) and Sintilimab injection 200mg Q3W (D1). Sintilimab injection will be administered until disease progressioncor un-tolerable toxicity. Anlotinib will be administered until disease progression. If anlotinib is not tolerated, the dose can be reduced to 10mg or 8mg ,until un-tolerable toxicity again.

NCT ID: NCT04042805 Recruiting - Clinical trials for Hepatocellular Carcinoma

Sintilimab Combined With Lenvatinib in Local Advanced Hepatocellular Carcinoma

Start date: August 1, 2019
Phase: Phase 2
Study type: Interventional

This ia a single-arm, single-center, not-randomized, open-label phase II study. The purpose of this study is to evaluate the efficacy and safety of Sintilimab (PD-1 antibody) combined with Lenvatinib(TKI) for the treatment of local advanced hepatocellular carcinoma.

NCT ID: NCT04035876 Recruiting - Clinical trials for Hepatocellular Carcinoma

Combination Camrelizumab (SHR-1210) and Apatinib for Downstaging/Bridging of HCC Before Liver Transplant

Start date: July 16, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

To assess the primary effects and safety of camrelizumab (SHR-1210) plus apatinib for downstaging/bridging of HCC before liver transplantation.